Heidelberg Epignostix develops AI-based bioinformatics algorithms that use DNA methylation patterns to improve cancer classification, prognosis and therapy management. Its lead product, the Heidelberg Brain Tumor Classifier, is currently available as a research-use-only resource. The company combines epigenetics with artificial-intelligence powered analysis to classify tumor subtypes that are otherwise hard or impossible to distinguish. The algorithm has been applied to more than 150,000 patient samples to date. Heidelberg Epignostix intends to use the funds to expand development efforts for its flagship indication in brain tumor classification. The startup is headquartered in Heidelberg, Germany.

Total raised

$5M

Funding rounds

1

Latest round

Seed

Latest activity

Jul 2024